The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy

被引:0
|
作者
Banerjee, S. N.
Thornhill, A.
Evans, D. B.
Littlewood-Evans, A. J.
Dowsett, M.
Martin, L-A
机构
[1] Inst Canc Res, London SW3 6JB, England
[2] Novartis Inst Biomed Res, Basel, Switzerland
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S8 / S8
页数:1
相关论文
共 50 条
  • [41] Phase I/III study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer.
    Schleucher, N
    Trarbach, T
    Junker, U
    Tewes, M
    Masson, E
    Lebwohl, D
    Seeber, S
    Laurent, D
    Vanhoefer, U
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 259S - 259S
  • [42] Ionizing radiation of canine melanoma xenografts in nude mice with and without PTK787/ZK 222584
    Inteeworn, N
    Ohlerth, S
    Hoepfl, G
    Roos, M
    Wergin, MC
    Bley, CR
    Gassmann, M
    Kaser-Hotz, B
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S279 - S279
  • [43] Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
    A Giatromanolaki
    M I Koukourakis
    E Sivridis
    K C Gatter
    T Trarbach
    G Folprecht
    M M Shi
    D Lebwohl
    T Jalava
    D Laurent
    G Meinhardt
    A L Harris
    British Journal of Cancer, 2012, 107 : 1044 - 1050
  • [44] Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584
    Thomas, AL
    Morgan, B
    Drevs, J
    Unger, C
    Wiedenmann, B
    Vanhoefer, U
    Laurent, D
    Dugan, M
    Steward, WP
    SEMINARS IN ONCOLOGY, 2003, 30 (03) : 32 - 38
  • [45] MRI-assessed changes in tumor blood flow after treatment with PTK787/ZK222584 (PTK/ZK) correlate with subsequent tumor shrinkage or growth in patients with metastatic renal cell carcinoma
    de Bazelaire, C
    Alsop, D
    Rofsky, N
    Wang, YY
    Mietlowski, W
    Reitsma, D
    Laurent, D
    Michaelson, D
    Kantoff, P
    George, D
    Oh, WK
    ANNALS OF ONCOLOGY, 2005, 16 : 17 - 17
  • [46] The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®)
    Gaumann, Andreas K. A.
    Drexler, Hannes C. A.
    Lang, Sven A.
    Stoeltzing, Oliver
    Diermeier-Daucher, Simone
    Buchdunger, Elisabeth
    Wood, Jeanette
    Bold, Guido
    Breier, Georg
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (06) : 2267 - 2277
  • [47] Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), or primary peritoneal (PPC) cancers
    Juretzka, M. M.
    Aghajanian, C.
    Hensley, M. L.
    Tew, W. P.
    Spriggs, D.
    Konner, J.
    Chiang, A. C.
    Pezzulli, S.
    Kim, M.
    Sabbatini, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
    Giatromanolaki, A.
    Koukourakis, M. I.
    Sivridis, E.
    Gatter, K. C.
    Trarbach, T.
    Folprecht, G.
    Shi, M. M.
    Lebwohl, D.
    Jalava, T.
    Laurent, D.
    Meinhardt, G.
    Harris, A. L.
    BRITISH JOURNAL OF CANCER, 2012, 107 (07) : 1044 - 1050
  • [49] PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization - Comments
    Piepmeier, JM
    Westphal, M
    NEUROSURGERY, 2004, 55 (02) : 432 - 432
  • [50] Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation
    Hlushchuk, Ruslan
    Riesterer, Oliver
    Baum, Oliver
    Wood, Jeanette
    Gruber, Guenther
    Pruschy, Martin
    Djonov, Valentin
    AMERICAN JOURNAL OF PATHOLOGY, 2008, 173 (04): : 1173 - 1185